Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer

被引：0
|
作者：
Rademaker-Lakhai, JM
Horenblas, S
Meinhardt, W
Stokvis, E
De Reijke, TM
Jimeno, JM
Lazaro, LL
Martin, JAL
Beijnen, JH
Schellens, JHM
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] Pharmamar SA, Madrid, Spain
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 56卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：469 / 469
页数：1
相关论文
共 50 条
  • [1] Phase I clinical and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer
    Rademaker-Lakhai, JM
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    de Reijke, TM
    Jimeno, JM
    Lopez-Lazaro, L
    Martin, JAL
    Beijnen, JH
    Schellens, JHM
    CLINICAL CANCER RESEARCH, 2005, 11 (05) : 1854 - 1862
  • [2] Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Schellens, JH
    Rademaker, JL
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Reijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Beijnen, JH
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3694S - 3694S
  • [3] Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.
    Beijnen, JH
    Rademaker-Lakhai, JM
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Rijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 146S - 146S
  • [4] Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
    R. Salazar
    H. Cortés-Funes
    E. Casado
    B. Pardo
    A. López-Martín
    C. Cuadra
    J. Tabernero
    C. Coronado
    M. García
    A. Soto Matos-Pita
    B. Miguel-Lillo
    M. Cullell-Young
    J. L. Iglesias Dios
    L. Paz-Ares
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 75 - 83
  • [5] Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors
    Pardo, Beatriz
    Paz-Ares, Luis
    Tabernero, Josep
    Ciruelos, Eva
    Garcia, Margarita
    Salazar, Ramon
    Lopez, Ana
    Blanco, Maria
    Nieto, Antonio
    Jimeno, Jose
    Izquierdo, Miguel Angel
    Trigo, Jose Manuel
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1116 - 1123
  • [6] Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
    Salazar, R.
    Cortes-Funes, H.
    Casado, E.
    Pardo, B.
    Lopez-Martin, A.
    Cuadra, C.
    Tabernero, J.
    Coronado, C.
    Garcia, M.
    Soto Matos-Pita, A.
    Miguel-Lillo, B.
    Cullell-Young, M.
    Iglesias Dios, J. L.
    Paz-Ares, L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 75 - 83
  • [7] Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study
    Rudek, MA
    Donehower, RC
    Statkevich, P
    Batra, VK
    Cutler, DL
    Baker, SD
    PHARMACOTHERAPY, 2004, 24 (01): : 16 - 25
  • [8] Population pharmacokinetics of kahalalide F in advanced cancer patients
    Miguel-Lillo, Bernardo
    Valenzuela, Belen
    Peris-Ribera, Jose Esteban
    Soto-Matos, Arturo
    Perez-Ruixo, Juan Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 365 - 374
  • [9] Population pharmacokinetics of kahalalide F in advanced cancer patients
    Bernardo Miguel-Lillo
    Belén Valenzuela
    José Esteban Peris-Ribera
    Arturo Soto-Matos
    Juan José Pérez-Ruixo
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 365 - 374
  • [10] Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma - A phase I and pharmacokinetic study
    Van Veldhuizen, PJ
    Reed, G
    Aggarwal, A
    Baranda, J
    Zulfiqar, M
    Williamson, S
    CANCER, 2003, 98 (09) : 1855 - 1862
12345